Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
3.740
+0.030 (+0.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Editas Medicine
< Previous
1
2
3
4
5
6
7
8
9
Next >
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
November 29, 2023
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.
Via
InvestorPlace
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year
November 22, 2023
Investors may want to strongly consider this new list of stocks to buy that could double in 2024. Check out these hidden gems.
Via
InvestorPlace
The 3 Best Gene Editing Stocks on the Frontier of Medicine
November 20, 2023
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.
Via
InvestorPlace
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
November 20, 2023
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?
Via
The Motley Fool
3 Long-Term Growth Stocks Analysts Are Bullish On
November 16, 2023
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two.
Via
InvestorPlace
A Preview Of Editas Medicine's Earnings
November 02, 2023
Via
Benzinga
Analyst Ratings for Editas Medicine
October 18, 2023
Via
Benzinga
Is Editas Stock a Buy Now?
October 07, 2023
Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now?
Via
The Motley Fool
Expert Ratings for Editas Medicine
September 29, 2023
Via
Benzinga
3 Biotech Stocks That Are Betting on the Future of Gene Editing
November 09, 2023
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.
Via
InvestorPlace
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 03, 2023
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.
Via
Benzinga
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
November 03, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
October 30, 2023
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.
Via
The Motley Fool
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.
Via
InvestorPlace
Earnings Scheduled For November 3, 2023
November 03, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
October 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
October 24, 2023
Via
Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
October 18, 2023
Both are in a race against time to commercialize a medicine before cash runs out.
Via
The Motley Fool
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
October 17, 2023
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 17, 2023
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!
Via
InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
October 17, 2023
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
October 05, 2023
It's key to understand the resources it will take to deliver a company's pipeline.
Via
The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
October 02, 2023
The better of the pair should be able to beat Bluebird Bio.
Via
The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
September 29, 2023
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Via
Benzinga
Why Editas Medicine Stock Is Soaring Today
September 29, 2023
Investors are cheering a big analyst upgrade for the gene-editing stock.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
September 29, 2023
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market...
Via
Benzinga
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
September 29, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.